Prognostic factors of final visual acuity in DME patients on anti-VEGF treatment in real life settings

Session Details

Session Title: Free Paper Session 7: Vascular Diseases & Diabetic Retinopathy II

Session Date/Time: Thursday 07/09/2017 | 14:30-16:00

Paper Time: 15:06

Venue: Room 117

First Author: : J.Stefanickova SLOVAKIA

Co Author(s): :    P. Krajcova   V. Krasnik                          

Abstract Details

Purpose:

To evaluate the correlation of the best corrected visual acuity (BCVA) after three uploading injections and two years BCVA outcome in response to anti-VEGF treatment for diabetic macular edema in real life settings.

Setting:

Post hoc analysis

Methods:

Post hoc analysis of patients with diabetic macular edema treated with ranibizumab 0.5 mg in PRN regimen. Statistical analysis was performed at baseline BCVA and BCVA at month 3, 6, 12, 18 and 24.

Results:

The mean baseline visual acuity in the group of 53 patients/64 eyes was 62,4 letters. At week 12 after 3 uploading doses of ranibizumab 0,5mg mean BCVA improvement was + 5.4 letters. At month 24 the final BCVA increased + 5,1 letters. Based on response at week 12 after three monthly ranibizumab injections patients were divided into three groups - group 1: gainers less than 5 letters, group 2: gainers 5 to 9 letters, and group 3: gainers 10 or more letters. The analysis found that the largest group of patients gained less than 5 letters (46,9%), than 10 or more letters (40,6%) and the smallest group of 25,9% eyes gained 5 to 9 letters. After three uploading injections final documented BCVA was in group 1 -1,2 letters and at month 24 -1,7 letters; in group 2 +6,7 letters, +6,2 letters and in group 3 +15,1 letters, 15,3 letters, respectively. The average number of received injections: 7,9 in group 1; 7,9 in group 2 and 6,7 in group 3.

Conclusions:

The visual acuity after three uploading injections seems to be one of the very strong prognostic factors for final visual acuity in DME patients after24 months antiVEGF treatment. It is important to identify poor responders early and switching to other available therapies that may bring the benefit to subset of patients.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy